ACHIEVING MORe FOR RNA TREATMENTs
Guided by our team of srRNA experts and with a customizable library of synthetic srRNA vectors and end-to-end development capabilities at our disposal, we are uniquely positioned to develop safe and effective srRNA immunotherapies that maximize impact for more patients.
Our story began in 2014
Replicate co-founders Nathaniel Wang, Ph.D. and Andy Geall, Ph.D. had spent years working together in RNA vaccine development.
An idea for a vector-driven platform
They started Replicate to answer the question, “If we wanted to create the best self-replicating RNA platform from scratch, how would we do it?”
Joining with former colleagues Herbert Kim Lyerly, M.D., and Zachary Hartman, Ph.D., professors of cancer research and immunology at Duke University, the founding team began to explore preventing or removing drug-resistant cancer mutations using srRNA.
The work begins
Replicate exclusively licensed from Duke technology to prevent drug-resistant cancer mutations. Then we got to work building new vectors from scratch.
We have since made rapid progress in identifying many promising srRNA preclinical candidates in infectious disease, oncology, and autoimmune diseases.
Learn more about our
Want to be a part of the next revolution in RNA therapeutics?